Ziftomenib
- Generic Name
- Ziftomenib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C33H42F3N9O2S2
- CAS Number
- 2134675-36-6
- Unique Ingredient Identifier
- 4MOD1F4ENC
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Ziftomenib, an Oral Menin Inhibitor, in Combination with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)
- Conditions
- Interventions
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 157
- Registration Number
- NCT06655246
A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT06448013
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Ziftomenib Maintenance Post Allo-HCT
- Conditions
- Interventions
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT06440135
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias
- Conditions
- Interventions
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT06397027
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Ziftomenib in Combination with Chemotherapy for Children with Relapsed/Refractory Acute Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- LLS PedAL Initiative, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT06376162
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 171
- Registration Number
- NCT06001788
- Locations
- 🇺🇸
The University of Kansas, Kansas City, Kansas, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Prisma Health, Greenville, South Carolina, United States
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Tanja Andrea Gruber
- Target Recruit Count
- 90
- Registration Number
- NCT05848687
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
Expanded Access to Ziftomenib
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Kura Oncology, Inc.
- Registration Number
- NCT05738538
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination with Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients with AML
- Conditions
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 212
- Registration Number
- NCT05735184
- Locations
- 🇺🇸
Moores UC San Diego Cancer Center, La Jolla, California, United States
🇺🇸USC University of Southern California / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA - Bowyer Oncology Center, Los Angeles, California, United States
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 199
- Registration Number
- NCT04067336
- Locations
- 🇺🇸
UCLA Bowyer Oncology Center, Los Angeles, California, United States
🇺🇸University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸University of Southern California, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.